Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra to treat patients in an increasingly competitive indication—transthyret | ...

Canaccord analyst Whitney Ijem raised the firm’s price target on Alnylam (ALNY) to $385 from $384 and keeps a Buy rating on the shares. The ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

Amvuttra is the medicine that can reduce the amount of abnormal proteins in your body to help decrease symptoms and possibly prevent further nerve damage. Hereditary transthyretin-mediated ...

Like other drugs, Amvuttra (vutrisiran) can cause side effects, such as difficulty breathing and low vitamin A levels. If you can’t tolerate side effects of Amvuttra, talk with your doctor.

ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher ...

Amvuttra (vutrisiran) is a prescription drug that’s used to treat nerve damage related to a rare genetic condition. Amvuttra is given as an injection under your skin by a healthcare professional.

Alnylam Pharmaceuticals Inc (ALNY) reports robust financial performance with a 33% revenue growth and outlines strategic ...

It has received multiple approvals for RNAi-based medicines such as Onpattro and Amvuttra, both of which are leading in the company's successful commercialization strategy. Under Alnylam’s ...